ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ceva santé animale sa-nv - metoclopramide hydrochloride 1 mg/ml - eq. metoclopramide 0,891 mg/ml - oral solution - 1 mg/ml - metoclopramide hydrochloride 1 mg/ml - metoclopramide - dog; cat

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - metoclopramide hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium hydroxide; hydrochloric acid; water for injections; nitrogen; sodium chloride - adults (20 years or older): - relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia. - control of post-operative vomiting - assist in small bowel intubation.,metoclopramide is of little benefit for the prevention or treatment of motion sickness.,young adults and children (over 1 year of age): metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects - severe intractable vomiting of known cause - vomiting associated with radiation therapy or intolerance to cytotoxic drugs. - assist in small bowel intubation

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

gavis pharmaceuticals, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - metoclopramide hydrochloride orally disintegrating tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (gerd) who fail to respond to conventional therapy. metoclopramide hydrochloride orally disintegrating tablets are indicated for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (gastric stasis) in adults. metoclopramide hydrochloride orally disintegrating tablets are indicated for adults only. therapy should not exceed 12 weeks in duration. the safety and effectiveness in pediatric patients have not been established. do not use metoclopramide whenever stimulation of gastrointestinal motility may be dangerous such as in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation. metoclopramide is contraindicated in patients with pheochromocytoma because the drug may precipitate a hypertensive crisis, most likely due to release of catecholamines from the tumor. such hyperte

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

ceva santé animale - metoclopramide (as hydrochloride) equivalent to metoclopramide hydrochloride ph. eur. - oral solution - 1 mg/ml - metoclopramide - canine, feline - miscellaneous

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - metoclopramide hydrochloride 1 mg/ml - syrup - 1 mg/ml - active: metoclopramide hydrochloride 1 mg/ml excipient: citric acid monohydrate essence of lime-flavour no.1(06-3607) hyetellose methyl hydroxybenzoate propyl hydroxybenzoate purified water saccharin sodium terpeneless lemon oil

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - metoclopramide hydrochloride -

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

lumacina new zealand - metoclopramide hydrochloride monohydrate 5.27 mg/ml equivalent to metoclopramide hydrochloride 5 mg/ml - solution for injection - 10 mg/2ml - active: metoclopramide hydrochloride monohydrate 5.27 mg/ml equivalent to metoclopramide hydrochloride 5 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - adults (20 years and over) · relief of nausea and vomiting associated with migraine, cancer therapy (chemotherapy or radiation), malignant disease, labour, infectious disease and uraemia · control of post-operative vomiting · assist in small bowel intubation metoclopramide is of little benefit for the prevention or treatment of motion sickness. young adults and children (over 1 year of age) metoclopramide should be restricted to the following conditions and only used as second line therapy, when used to treat children and young adults under 20 years of age because of the risk of adverse effects. · severe intractable vomiting of known cause · vomiting associated with radiation therapy or intolerance to cytotoxic drugs · assist in small bowel intubation

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation